<DOC>
	<DOC>NCT00543972</DOC>
	<brief_summary>The primary objective is to determine the maximum tolerated dose of AVE9633 and to characterize the dose limiting toxicity(ies). Secondary objectives are to determine the anti-leukemia activity, the global safety and the PK profile.</brief_summary>
	<brief_title>Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Patients with CD33positive acute myeloid leukemia, refractory or relapsed after standard treatment with no curative option available ECOG performance status 0 to 2 Therapy with gemtuzumab ozogamicin (Mylotarg) within 6 months prior to inclusion Allogenic transplantation within 6 months prior to inclusion Prior therapy (chemotherapy, targeted agents, radiotherapy) within 3 weeks except for hydroxyurea and for leukophoresis Previous treatment with AVE9633 Poor kidney, liver and bone marrow functions Any serious active disease or comorbid condition, which in the opinion of the principle investigator, will interfere with the safety or with compliance with the study Pregnant or breastfeeding women Patient with reproductive potential without effective birth control methods The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>